Data gathered: January 2
Alternative Data for Cassava Sciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 70 | Sign up | Sign up | Sign up |
| Webpage traffic | 159,000 | Sign up | Sign up | Sign up |
| Google Trends | 2 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 19 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 54,594 | Sign up | Sign up | Sign up |
| Twitter Mentions | 31 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 37 | Sign up | Sign up | Sign up |
About Cassava Sciences
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.
| Price | $2.61 |
| Target Price | Sign up |
| Volume | 863,310 |
| Market Cap | $114M |
| Year Range | $2.29 - $35.08 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SAVAJanuary 1 - Investing.com |
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJanuary 1 - GlobeNewswire |
|
ROSEN, A TOP-RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVADecember 30 - GlobeNewswire |
|
Shareholders that lost money on Cassava Sciences, Inc.(SAVA) should contact Levi & Korsinsky about pending Class Action - SAVADecember 30 - Finnhub |
|
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming DeadlineDecember 30 - GlobeNewswire |
|
Class Action Announcement (SAVA): A Securities Fraud Class Action Lawsuit Was Filed Against Cassava Sciences, Inc. (SAVA)December 30 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 13M | -13M | -28M | -31M | -0.580 |
| Q2 '24 | 0 | 46M | -46M | 6.2M | -61M | 0.130 |
| Q1 '24 | 0 | 3.8M | -3.8M | 25M | -20M | 0.580 |
| Q4 '23 | 2.3M | 4.1M | -4.1M | -21M | -23M | -0.500 |
| Q3 '23 | 0 | 4.4M | -4.4M | -26M | -28M | -0.610 |
Insider Transactions View All
| Schoen Eric filed to sell 11,500 shares at $3.9. December 3 '24 |
| ROBERTSON SANFORD filed to buy 886,851 shares at $17.5. August 24 '23 |
| Barry Richard filed to buy 293,477 shares at $16.7. August 23 '23 |
Similar companies
Read more about Cassava Sciences (SAVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cassava Sciences?
The Market Cap of Cassava Sciences is $114M.
What is the current stock price of Cassava Sciences?
Currently, the price of one share of Cassava Sciences stock is $2.61.
How can I analyze the SAVA stock price chart for investment decisions?
The SAVA stock price chart above provides a comprehensive visual representation of Cassava Sciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cassava Sciences shares. Our platform offers an up-to-date SAVA stock price chart, along with technical data analysis and alternative data insights.
Does SAVA offer dividends to its shareholders?
As of our latest update, Cassava Sciences (SAVA) does not offer dividends to its shareholders. Investors interested in Cassava Sciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cassava Sciences?
Some of the similar stocks of Cassava Sciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.